Back to Journals » Biologics: Targets and Therapy » Volume 8
Biologics: Targets and Therapy
ISSN: 1177-5491
- View all (501)
- Volume 18, 2024 (5)
- Volume 17, 2023 (17)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Archive: Volume 8, 2014
Multikinase inhibitors use in differentiated thyroid carcinoma
Jasim S, Ozsari L, Habra MA
Biologics: Targets and Therapy 2014, 8:281-291
Published Date: 4 December 2014
Inactivation of chromatin remodeling factors sensitizes cells to selective cytotoxic stress
Freeman MD, Mazu T, Miles JS, Darling-Reed S, Flores-Rozas H
Biologics: Targets and Therapy 2014, 8:269-280
Published Date: 14 November 2014
Targeted alpha anticancer therapies: update and future prospects
Allen BJ, Huang CY, Clarke RA
Biologics: Targets and Therapy 2014, 8:255-267
Published Date: 10 November 2014
Resistant mutations in CML and Ph+ALL – role of ponatinib
Miller GD, Bruno BJ, Lim CS
Biologics: Targets and Therapy 2014, 8:243-254
Published Date: 20 October 2014
Botulinum toxin type A products are not interchangeable: a review of the evidence
Brin MF, James C, Maltman J
Biologics: Targets and Therapy 2014, 8:227-241
Published Date: 6 October 2014
New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
Frati F, Cecchi L, Scala E, Ridolo E, Dell'Albani I, Makrì E, Pajno G, Incorvaia C
Biologics: Targets and Therapy 2014, 8:221-226
Published Date: 12 September 2014
Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists
Urbano PCM, Soccol VT, Azevedo VF
Biologics: Targets and Therapy 2014, 8:211-220
Published Date: 31 July 2014
Golimumab in unresponsive ulcerative colitis
Lippert E, Müller M, Ott C
Biologics: Targets and Therapy 2014, 8:207-210
Published Date: 27 May 2014
Plasma membrane coenzyme Q: evidence for a role in autism
Crane FL, Löw H, Sun I, Navas P, Gvozdjáková A
Biologics: Targets and Therapy 2014, 8:199-205
Published Date: 29 May 2014
Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis
Alawneh KM, Ayesh MH, Khassawneh BY, Saadeh SS, Smadi M, Bashaireh K
Biologics: Targets and Therapy 2014, 8:193-198
Published Date: 22 April 2014
Clinical and comparative utility of afatinib in non-small cell lung cancer
D'Arcangelo M, Hirsch FR
Biologics: Targets and Therapy 2014, 8:183-192
Published Date: 23 April 2014
Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
Kivelevitch D, Mansouri B, Menter A
Biologics: Targets and Therapy 2014, 8:169-182
Published Date: 17 April 2014
Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
Davis-Ajami ML, Wu J, Downton K, Ludeman E, Noxon V
Biologics: Targets and Therapy 2014, 8:155-167
Published Date: 16 April 2014
Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors
Tanaka T, Hishitani Y, Ogata A
Biologics: Targets and Therapy 2014, 8:141-153
Published Date: 7 April 2014
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
Stjepanovic N, Capdevila J
Biologics: Targets and Therapy 2014, 8:129-139
Published Date: 10 April 2014
Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method
Berntorp E, Spotts G, Patrone L, Ewenstein BM
Biologics: Targets and Therapy 2014, 8:115-127
Published Date: 5 April 2014
Biologics: the role of delivery systems in improved therapy
Škalko-Basnet N
Biologics: Targets and Therapy 2014, 8:107-114
Published Date: 19 March 2014
Targeted therapy for sarcomas
Forscher C, Mita M, Figlin R
Biologics: Targets and Therapy 2014, 8:91-105
Published Date: 17 March 2014
Porcine dermis implants in soft-tissue reconstruction: current status
Smart NJ, Bryan N, Hunt JA, Daniels IR
Biologics: Targets and Therapy 2014, 8:83-90
Published Date: 10 March 2014
Update on the use of systemic biologic agents in the treatment of noninfectious uveitis
Pasadhika S, Rosenbaum JT
Biologics: Targets and Therapy 2014, 8:67-81
Published Date: 15 February 2014
Does the cis/trans configuration of peptide bonds in bioactive tripeptides play a role in ACE-1 enzyme inhibition?
Siltari A, Viitanen R, Kukkurainen S, Vapaatalo H, Valjakka J
Biologics: Targets and Therapy 2014, 8:59-65
Published Date: 11 February 2014
Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [Corrigendum]
Thorlund K, Druyts E, Aviña-Zubieta JA, Mills EJ
Biologics: Targets and Therapy 2014, 8:57-58
Published Date: 7 February 2014
A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations
Wells AF, Jodat N, Schiff M
Biologics: Targets and Therapy 2014, 8:41-55
Published Date: 17 February 2014
Biologic targeting in the treatment of inflammatory bowel diseases [Retraction]
Bosani M, Ardizzone S, Porro GB
Biologics: Targets and Therapy 2014, 8:39-40
Published Date: 31 January 2014
Therapeutic vaccines and cancer: focus on DPX-0907
Karkada M, Berinstein NL, Mansour M
Biologics: Targets and Therapy 2014, 8:27-38
Published Date: 10 February 2014
Ziv-aflibercept in metastatic colorectal cancer
Patel A, Sun W
Biologics: Targets and Therapy 2014, 8:13-25
Published Date: 16 December 2013
Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis
Paula FS, Delgado Alves J
Biologics: Targets and Therapy 2014, 8:1-12
Published Date: 9 December 2013